The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

GHK-Cu

Research chemical · Grade C

Goals
healing, beauty, longevity
Evidence
2 RCT / 4 animal / 6 in vitro
Routes
topical, injectable-sc, scalp, oral, nasal
WADA
No
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
TGF-beta collagen synthesis
View full report →

BPC-157

Research chemical · Grade C

Goals
healing, gut
Evidence
0 RCT / 35 animal / 0 in vitro
Routes
injectable-im, injectable-sc, oral
WADA
S0
FDA
Not approved
Cancer caution
hard-stop
Typical dose
250-500 mcg/day SubQ or IM. Acute injury: 500 mcg twice daily. Oral (gut): 500 mcg-1 mg/day. Cycle 6-8 weeks on, 4 weeks off.
Half-life
—
Primary mechanism
VEGFR2-Akt-eNOS angiogenesis
View full report →

GHK (Basic)

Research chemical · Grade C

Goals
beauty, healing, longevity
Evidence
2 RCT / 4 animal / 5 in vitro
Routes
topical, scalp
WADA
No
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Dasatinib + Quercetin

Off-label · Grade C

Goals
healing, longevity, immune
Evidence
0 RCT / 0 animal / 0 in vitro
Routes
oral
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
Half-life: 3-5 hours
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →